Assessing Safety and Efficacy of Sintilimab and Metformin Combination Therapy in SCLC
Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
In this Single arm study, histologically or cytologically confirmed ED-stage small cell lung
cancer (SCLC) patients resistant to or relapsed after standard chemotherapy will be enrolled
to investigate the Efficacy and Safety of a Combination of Sintilimab and Metformin.
Primary outcome:
Objective response rate (ORR), Safety of the combination therapy
Secondary outcome:
Overall survival (OS), Progression-free survival (PFS), Duration of response(DOR),
Phase:
Phase 2
Details
Lead Sponsor:
Hunan Cancer Hospital
Collaborators:
Innovent Biologics (Suzhou) Co. Ltd. Xiangya Hospital of Central South University